SALVO SPAGNA Global Chairman & Chief Executive Officer

Salvo Spagna leads EDE Pharmaceuticals with a simple yet profound belief: science only has value when it can concretely improve people’s lives.

Under his leadership, EDE has built an environment where innovation, responsibility, and humanity coexist every day. He believes that addressing the most complex diseases requires not only technology and advanced research, but also the courage to think differently and move beyond the limits of traditional models.

His approach combines strategic vision with constant operational involvement. He works to ensure that scientific discoveries do not remain theory or numbers on a screen, but become real, accessible therapies capable of reaching the people who need them quickly.

Through the integration of artificial intelligence, molecular simulation, and applied research, EDE Pharmaceuticals accelerates the development of new therapeutic solutions while always keeping the human value of every decision at the center.

For Salvo Spagna, behind every data point, every simulation, and every research project, there is a person waiting for hope. This awareness is what guides the work of the entire institute.

More than a scientific or industrial activity, he considers EDE Pharmaceuticals a responsibility toward humanity: transforming innovation and technology into treatments capable of reducing suffering, saving lives, and building a better future.

Rima Ramadan is a business development leader with over 20 years of experience across the genomics and pharmaceutical industries. She holds a Master’s degree in Business Administration from the University of East London and brings more than 12 years of dedicated experience in strategic partnerships and global licensing.

At EDE Pharmaceuticals, Rima leads the expansion of global collaborations with a clear vision: to fully leverage EDE’s existing innovation cycle to transform therapeutic solutions and ultimately save patients’ lives. In her view, the core purpose of this pharmaceutical line is to advance cutting-edge innovation by offering differentiated and innovative assets that can reshape treatment outcomes.

Rima’s philosophy is rooted in building strong partnerships with leading pharmaceutical companies to translate scientific innovation into real-world therapies. She believes that integrating genomic insights into drug development can deliver more effective and safer treatments, with the potential to reduce side effects and significantly improve patient outcomes.